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Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably 1, 2 . In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR) 3, 4 . Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex determining region Y-box 10 (SOX10) in melanoma causes activation of TGF-b signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-b (PDGFRB), which confer resistance to BRAF and MEK inhibitors. Expression of EGFR in melanoma or treatment with TGF-b results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence. However, EGFR expression or exposure to TGF-b becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors. In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-b signalling in 4 of the 6 EGFR-positive drugresistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Activating mutations in the BRAF oncogene are found in over half of the patients with advanced melanoma 5, 6 . Inhibition of the oncogenic BRAF protein with the small molecule inhibitor PLX4032 (vemurafenib) or its downstream effector MEK with GSK1120212 (trametinib) have shown impressive initial responses in patients with BRAF mutant melanoma 1, 2 . However, single-agent therapies for advanced cancers are rarely curative, due to the rapid development of resistance. To date, several drug resistance mechanisms have been identified in melanomas treated with vemurafenib, including increased expression of the gene encoding the COT kinase, mutation of downstream MEK1 (also known as MAP2K1) kinase, NRAS mutations and amplification or alternative splicing of the BRAF gene [7] [8] [9] [10] [11] . Moreover, increased expression of receptor tyrosine kinases (RTKs) has been observed as a mechanism of BRAF inhibitor resistance [11] [12] [13] . It has been shown recently that intrinsic resistance of BRAF mutant colon cancers to vemurafenib is the result of feedback activation of EGFR when BRAF is inhibited 3, 4 . To investigate whether BRAF(V600E) mutant melanoma patients frequently develop resistance to BRAF or MEK inhibitors through acquired expression of EGFR in their tumours, we obtained biopsies from BRAF(V600E) mutant melanomas from 16 patients treated with either the MEK inhibitor trametinib (n 5 1) or the BRAF inhibitors dabrafenib (n 5 3) or vemurafenib (n 5 12). Tumour biopsies collected both before treatment initiation and after the development of drug resistance were stained for EGFR expression. We found that 6 out of 16 post-treatment biopsies gained notable EGFR expression as judged by immunohistochemistry (Fig. 1a, b and Supplementary Table 1) .
Melanomas are derived from the neural crest and in general do not express EGFR
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. Hence, acquired EGFR expression during drug selection may represent a stress response that is not favoured in the absence of drug treatment. Indeed, the proliferation rate of A375 BRAF(V600E) melanoma cells 3 engineered to express EGFR decreased as the concentration of EGFR ligand increased (Fig. 1c) . Moreover, A375 cells that express EGFR also proliferate slowly compared to parental control cells in nude mouse xenografts, but are resistant to trametinib (Fig. 1d) . To investigate the cause of this slow-growth phenotype, we performed western blotting for a number of cell-cycle-associated proteins on parental A375 cells and EGFR-expressing derivatives. EGFR expression resulted in hypophosphorylated pRB protein, induction of the CDK inhibitors CDKN1A (p21 cip1 ) and CDKN1B (p27 kip1 ) and acidic b-galactosidase (Fig. 1e, f) , markers that have been associated with oncogene-induced senescence 15, 16 . These markers were also induced upon expression of oncogenic versions of BRAF or MEK, but much less when activated mutants of AKT1 or PIK3CA were expressed in A375 cells (Extended Data Fig. 1 ). We conclude that EGFR expression is disadvantageous for BRAF(V600E) melanoma cells in the absence of BRAF or MEK inhibitor drugs, but it confers a selective advantage in the presence of these drugs.
Acquired EGFR expression may be the result of an adaptive response of the cancer cell population during drug selection. To ask in an unbiased way which factors might modulate EGFR expression in melanoma cells, we compiled a 'chromatin regulator' library of shRNAs targeting 661 genes, including the lysine acetyltransferases (KATs), lysine methyltransferases (KMTs), lysine deacetylases (KDACs), lysine demethylases (KDMs), chromatin remodelling complexes and proteins that harbour chromatin binding/associated domains (Supplementary Table 2 ). A375 melanoma cells, which express very low levels of EGFR, were infected with the chromatin regulator library and selected with vemurafenib for 3 weeks. Then the vemurafenib-resistant cells were collected and strongly EGFR-positive cells (EGFR hi population by fluorescence-activated cell sorting (FACS) using an anti-EGFR antibody (Fig. 2a) . Treatment of cells with either the chromatin regulator library or vemurafenib alone did not increase the fraction of EGFR hi cells. In contrast, a significant fraction of EGFR hi cells could be retrieved when cells were infected with the chromatin regulator library and were selected for vemurafenib resistance (Fig. 2b) . We conclude that EGFR hi melanoma cells do not merely appear as a consequence of silencing of certain chromatin regulators, but that these cells only emerge when the population is placed under drug-selection pressure. This indicates that silencing of the gene(s) that induce EGFR expression is not favoured in the absence of vemurafenib.
To identify which gene(s) in the chromatin regulator library when suppressed can induce EGFR expression, we isolated genomic DNA from the EGFR hi cells and non-drug-treated control cells and determined the abundance of the shRNA vectors in each cell population by deep sequencing, as described previously 3 . shRNAs that confer resistance to vemurafenib through upregulation of EGFR should be enriched in the EGFR hi fraction. shRNA screens are notorious for yielding false positive results. Therefore, in principle only those genes that are represented by multiple shRNAs should be followed up in a genetic screen 17 .
However, in this screen we did not identify any genes for which more than one shRNA was enriched (Supplementary Table 3 ). We therefore focused on the top 10 most strongly enriched genes for follow-up experiments. We tested several additional shRNA vectors for each of ) and CDKN1B (p27 kip1 ) in EGFR expressing A375 cells. HSP90 served as a loading control. f, EGFR expression induces senescence. Senescence was detected by staining of b-galactosidase activity. All experiments shown, except the ones that involve clinical samples and animals, were performed independently at least 3 times. LETTER RESEARCH these 10 genes for their ability to increase EGFR expression, as this was a selection criterion in the genetic screen (Extended Data Fig. 2a, b) . Only suppression of the SRY (sex determining region Y)-box 10 (SOX10) gene induced prominent EGFR expression when multiple SOX10 shRNAs (shSOX10) were used in four melanoma cell line models (Fig. 2c, d and Extended Data Figs 2c, 4c and 5c). SOX10 knockdown (SOX10 KD ) induced a slow-growth phenotype and also displayed the hallmarks of oncogene-induced senescence in three melanoma models (Fig. 2e and Extended Data Figs 2e, f, g, 4b, e, f and 5b, e, f).
Next we confirmed that SOX10 KD indeed induced vemurafenib resistance in melanoma. We infected A375 cells with shSOX10 and cultured cells in the presence of vemurafenib. SOX10
KD slowed down proliferation of A375 cells in the absence of drug, but in the presence of vemurafenib SOX10 KD conferred drug resistance in both short-term and longterm assays (Fig. 2e and Extended Data Fig. 2d, e) . Moreover, under vemurafenib selective pressure, cells having a higher degree of SOX10 KD were selected, which consequently also expressed higher levels of EGFR, consistent with the notion that increased EGFR levels drive drug resistance (Extended Data Fig. 2h ). Vemurafenib resistance through SOX10 suppression was also seen in additional melanoma cell lines (Extended Data Figs 4a and 5a). A low concentration of vemurafenib actually increased the proliferation rate of SOX10 KD cells, consistent with the model that hyperactive BRAF-MEK signalling induces senescence markers, a process which is inhibited by vemurafenib (Extended Data Fig. 4a, g ).
To study how SOX10 suppression induces EGFR expression, we performed transcriptome sequencing (RNA-seq) of both parental A375 and A375 SOX10 KD cells (Supplementary Table 4 ). Gene set enrichment analysis of the SOX10-upregulated genes revealed an enrichment of genes with SMAD2/3 (downstream mediators of TGF-b signalling) and JUN binding sites in their promoters (Supplementary Table 5) . Consistent with this, SOX10 suppression induced TGF-b receptor 2 (TGFBR2) expression as well as a number of bona fide TGF-b target genes, including JUN, in three melanoma cell models (Fig. 3a, b and Extended Data Figs 4d and 5d). Levels of active JUN (phosphorylated JUN, p-JUN) were also increased by SOX10 KD (Fig. 3a) . That treatment of melanoma cells with recombinant TGF-b causes resistance to vemurafenib further supports a role for TGF-b signalling in vemurafenib resistance ( Fig. 3c and ref. 18 ). TGF-b1 treatment caused not only induction of EGFR expression, but also induction of PDGFRB (Fig. 3d, e) and also resulted in induction of senescence-associated b-galactosidase (Fig. 3f) . Consistently, SOX10 suppression also induced PDGFRB expression (Extended Data Figs 3c, 4c and 5c). Moreover, suppression of TGFBR2 inhibited EGFR and PDGFRB induction in SOX10 KD cells (Figs 3g, h ), whereas ectopic expression of TGFBR2 induced p-JUN, EGFR and PDGFRB expression (Fig. 3i) . JUN is a regulator of EGFR expression and TGF-b regulates PDGFRB [19] [20] [21] . Moreover, SMADs and JUN cooperate in activation of EGFR expression 22, 23 . SOX10 is known to regulate the melanocyte transcription factor MITF 24 . Indeed, A375 cells with shSOX10 also had reduced MITF expression, but MITF suppression alone did not change EGFR or PDGFRB expression and did not cause vemurafenib resistance (Extended Data Fig. 7c-e) . Our data provide support for a model in which activation of TGF-b signalling by SOX10 loss leads to increased EGFR and PDGFRB expression and vemurafenib resistance.
Treatment of A375-SOX10 KD cells with a combination of both vemurafenib and the EGFR inhibitor gefitinib did not lead to proliferation arrest, indicating that EGFR was not the sole driver of drug resistance in SOX10 KD cells (Extended Data Fig. 3a) . Indeed, an unbiased survey of RTKs revealed that SOX10 KD activated not only EGFR, but also PDGFRB and ERBB3 (Extended Data Fig. 3b, c) . A similar pattern of RTK activation was observed following TGF-b1 treatment, highlighting the similarity between SOX10 suppression and acquired TGF-b signalling (Extended Data Fig. 3b, d ). Many RTKs share two major downstream signalling pathways (RAS-MEK-ERK and PI3K-AKT). Consistent with this, we found that combined inhibition of these two downstream pathways using BRAF and PI3K inhibitors could restore growth inhibition in SOX10 KD cells (Extended Data Fig.  3a) .
Our data are consistent with a model in which cells with low SOX10 and high EGFR and PDGFRB expression are positively selected in the presence of drug, but that such cells are counter-selected in the absence of drug. To test this model directly, we infected A375 cells with shSOX10 and subjected this heterogeneous population of SOX10 KD cells to vemurafenib selection for one week. At this point, we collected part of this population and determined EGFR expression by FACS analysis. Under 21 recombinant TGF-b for 14 days. Senescence was detected by staining of b-galactosidase activity. g, h, SOX10 loss induced EGFR and PDGFRb upregulation is TGFBR2-dependent. A375 cells were infected with lentiviral shRNA vectors as indicated. Relative mRNA levels of EGFR and PDGFRB were determined by qRT-PCR analysis; EGFR, PDGFRb, TGFBR2 and SOX10 levels were determined by western blot analysis. Error bars represent s.d. of replicate measurements (n 5 3). i, TGFBR2 overexpression is sufficient to upregulate EGFR and PDGFRb. TGFBR2 was introduced to A375 cells by lentiviral transduction (TGFBR2, pLX304-TGFBR2). pLX304-GFP served as a control vector (Ctrl). The levels of EGFR, PDGFRb, TGFBR2, p-JUN and JUN were determined by western blot analysis. All experiments shown except RNA-seq were performed independently at least 3 times.
RESEARCH LETTER vemurafenib selection, an increased level of EGFR and a markedly decreased level of SOX10 were observed. When these cells were subsequently cultured for one more week in the absence of vemurafenib, the EGFR hi SOX10 lo population was depleted ( Fig. 4a and Extended Data Fig. 6a ). These data indicate that acquired EGFR expression is only advantageous to melanoma cells in the presence of drug selection, but is counter-selected in the absence of drug.
Consistent with a role for SOX10 in regulation of EGFR expression in melanoma, we found an inverse correlation between SOX10 and EGFR expression in a panel of 34 melanoma cell lines 25 ( Fig. 4b) and a similar inverse relationship between SOX10 and PDGFRB (Extended Data Fig. 6b) . The most extreme cell line in this panel, LOXIMVI, completely lacked SOX10 expression and had the highest EGFR expression. When we expressed SOX10 in this cell line, EGFR and PDGFRB were reduced and TGFBR2 and TGFBR3 as well as JUN and p-JUN levels were also downregulated, consistent with the notion that SOX10 regulates these RTKs through an effect on TGF-b signalling (Extended Data Fig. 6c, d) . Consistently, expression of SOX10 in LOXIMVI cells increased their sensitivity to vemurafenib (Extended Data Fig. 6e ).
To ask directly whether SOX10 is involved in EGFR-associated drug resistance in BRAF(V600E) melanoma patients, we isolated RNA from the six patients studied above who had gained EGFR expression after acquisition of trametinib, dabrafenib or vemurafenib resistance (Supplementary Table 1 ). We performed RNA-seq analysis to determine changes in transcriptome upon drug resistance. In two patients, the levels of SOX10 mRNA were reduced (Fig. 4c and Extended Data  Fig. 6f ). EGFR and PDGFRB mRNA were greatly increased in patient 5, whereas no evidence was found in this patient of alternative BRAF splicing 7 or BRAF overexpression (Extended Data Fig. 7a, b) . Patient 3 had strong induction of EGFR protein post-resistance (Fig. 1a) , but at first glance, EGFR mRNA levels appeared only minimally induced. However, scrutiny of the RNA-seq data revealed that the apparent lack of induction of EGFR in this tumour sample pair is caused by the abnormally high EGFR transcript abundance in the pre-treatment Consequently, vemurafenib is no longer able to fully silence the signalling to MEK and drug resistance is seen. When the drug is removed, supra-physiological levels of BRAF-MEK signalling induced a state of oncogene-induced senescence, which subsequently leads to negative selection of the RTKs and restores drug responsiveness. All experiments shown, except the ones that involve clinical samples, were performed independently at least 3 times.
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sample and not the lack of EGFR expression in the post-treatment sample (Extended Data Fig. 6g ). This is most probably owing to the contamination of this sample with the strongly EGFR-positive skin material (see Fig. 1a ). These tumours also manifested increased TGF-b signalling ( Fig. 4c and Extended Data Fig. 6h) . Two further pairs of tumour samples showed induction of EGFR and PDGFRB without notable loss of SOX10 after drug resistance emerged. These tumours displayed induction of TGF-b receptor expression and induction of a number of bona fide TGF-b targets, indicating that these tumours somehow had acquired TGF-b signalling (and subsequent induction of EGFR and PDGFRB expression) in a SOX10-independent fashion (Fig. 4c) .
Clinical evidence indicates that melanoma patients that have developed vemurafenib resistance can regain sensitivity to the drug after a drug holiday, suggesting a reversible and adaptive transcriptional response to the drug 26 . That drug resistance is reversed in the absence of drug indicates that this adaptive response is not favoured in the absence of drug. Our data provide a molecular underpinning for the concept that drug resistance may arise at a fitness cost in the absence of drug (Fig. 4d) . Melanoma patients whose tumours acquire EGFR expression as a result of drug resistance development may be candidates to be re-treated with drug after a drug holiday.
METHODS SUMMARY
Pooled shRNA Screen. A 'chromatin regulator' shRNA library targeting 661 genes was constructed from the TRC human genome-wide shRNA collection (TRC-Hs1.0). Lentiviral shRNA vectors generated from the pooled library were used to infect A375 cells. Cells stably expressing shRNA were selected by vemurafenib and then FACS sorted for EGFR expression. Massive parallel sequencing was used to determine the enriched shRNA in the selected cell population. Melanoma patient tumour samples. Permission was granted by the NKI and IGR ethical committee to take biopsies from BRAF(V600E) mutant patients before and after vemurafenib, dabrafenib or trametinib treatment. All patients consented to participate in the study. BRAF(V600E) mutation status was determined by Departments of Pathology at NKI and IGR.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Cell lines. The A375 melanoma cell line was obtained from ATCC. SK-MEL-28 and COLO679 were gifts from D. Peeper (Amsterdam, The Netherlands). WM266-4 cell line was provided by R. Marais (Manchester, UK) A375 and WM266-4 cells were cultured in DMEM medium supplemented with 8% FBS, 1% penicillin/streptomycin and 2 mM L-glutamine. COLO679 cell was cultured in RPMI medium supplemented with 8% FBS, 1% penicillin/streptomycin and 2 mM L-glutamine. Compounds, antibodies and reagents. Trametinib (#S2673), vemurafenib (# S1267), gefitinib (#S1025) and GDC0941 (#S1065) were purchased from Selleck Chemicals. TGF-b1 was purchased from R&D (#240-B-010).
Antibodies against HSP90 (H-114), p21 (C-19), TGFBR2 (C-16), p-c-JUN (KM-1) and c-JUN (N) were from Santa Cruz Biotechnology; anti-EGFR for FACS application (GR01L) was from Millipore; anti-EGFR for western blot analysis (610017), RB (554136) and p27 (610242) antibodies and RTK arrays were from BD Biosciences; Antibodies against TGFBR3(#2519), p-RB (#9307), p-MEK(#9154), MEK (#4694) and PDGFRB(#4564, #3166) were from Cell Signaling; antibody against SOX10 (ab155279) was from Abcam. CellTiter-Blue Cell Viability Assay was from Promega. Plasmids. Individual shRNA vectors used were collected from the TRC library (Supplementary Table 6 ). The following plasmids were purchased from Addgene to generate pLX304-EGFP, pLX301-SOX10, pLX304-EGFR, pLX301-EGFR and pLX304-TGFBR2 constructs by Gateway cloning 8, 27, 28 . Plasmid 24749: pDONR221-hSOX10; Plasmid 25890: pLX304; Plasmid 25895: pLX301; Plasmid 25899: pDONR221_EGFP; Plasmid 23935: pDONR223-EGFR; Plasmid 23623: pDONR223-TGFBR2. FACS-assisted shRNA screen with a customized library. Lentiviral vectors (pLKO.1) encoding shRNAs that target chromatin regulator genes are listed in Supplementary  Table 2 . The chromatin regulator library contains six plasmids pools. Lentiviral supernatants of the plasmids were produced as described at (http://www.broadinstitute.org/ rnai/public/resources/protocols). A375 cells were infected independently by the six virus pools (multiplicity of infection , 1) and selected with puromycin (2 mg ml 21 ) for cells containing integrated shRNA. Cells were then pooled and seeded at 350,000 cells per 15 cm dish in the absence or presence of 0.5 mM vemurafenib (8 dishes for each condition) for 21 days. The medium was refreshed every 3 days. The cells without vemurafenib treatment were collected at day 12. At day 21, the cells treated with vemurafenib were collected using 2 mM EDTA (#E4884, Sigma-Aldrich). Then, the cells were stained with mouse anti-human EGFR antibody primarily (#GR01L, Clone 528, Millipore), followed by secondary staining with Alexa Fluor 647 conjugated goat anti-mouse IgG antibody (#A-21236, Invitrogen), after which the cells were washed and suspended in DMEM medium containing 2% FBS. BD FACSAria III (BD Bioscience) was used to sort out EGFR hi cells. The FACS data was analysed by FlowJo programme version 7.6.3 (Tree Star). The genomic DNA was isolated from non-drugtreated control cells and drug-treated EGFR hi cells using DNeasy Blood and Tissue Kit (#69506 Qiagen). shRNA inserts were recovered from 500 ng genomic DNA following by the experimental steps of PCR amplification (PCR1 and PCR2) as described 3 . PCR product purification was performed using High Pure PCR Product Purification Kit according to the manufacturer's instructions (#11732676001, Roche). Purified PCR products were subjected to deep sequencing to identify the shRNA inserts. Staining of b-galactosidase activity. For Fig. 1f, Extended Data Fig. 2f and Extended Data Fig. 4e , the staining method is as follows. Cells were washed with PBS and fixed with 0.5% glutaraldehyde solution (in PBS pH 7.4) for 15 min at room temperature. Then the cells were washed with PBS for 5 min and with 0.925 mM MgCl 2 solution (in PBS pH 6.0) twice for 5 min at room temperature. X-gal staining solution (freshly prepared) was added to the cells and the incubation was performed at 37 uC for 8 h to overnight. Cells were washed again 3 times with PBS for 5 min at room temperature before the pictures were taken.
For , mice were randomized into treatment arms and treated for a 21-day period. Trametinib was formulated in 0.5% hydroxypropylmethylcellulose (Sigma) and 0.2% Tween-80 in distilled water pH 8.0, and it was dosed at 0.15 mg per kg daily by oral gavage. All animal procedures were approved by the Ethical Commission of the University of Turin and by the Italian Ministry of Health and they were performed in accordance with institutional guidelines. Melanoma patient tumour samples. Permission was granted by the NKI or IGR ethical committee to take biopsies from BRAF(V600E) mutant patients before and after vemurafenib, dabrafenib or trametinib treatment. All patients consented to participate in the study. BRAF(V600E) mutations were determined by Department of Pathology at NKI or IGR. Immunohistochemistry. For EGFR staining, FFPE samples, immunohistochemistry was performed on a BenchMark Ultra autostainer (Ventana Medical Systems, Inc.) Briefly, paraffin sections were cut at 4 mm, heated at 75 uC for 28 min and deparaffinized in the instrument with EZ prep solution (Ventana Medical Systems). Heat-induced antigen retrieval was carried out using Cell Conditioning 1 (CC1, Ventana Medical Systems). EGFR was detected by incubating sections with antibody clone 5B7 (5278457001; Roche (Ventana)) for 16 min. Specific reactions were detected using UltraView Universal Alkaline Phosphatase Red Detection or DAB Kit (Ventana Medical Systems), and slides were counterstained with haematoxylin. EGFR staining, fresh-frozen samples. Fresh-frozen sections (4-mm thick) were mounted on 3-aminopropylethoxysilane (Sigma) and glutaraldehyde coated slides. After 10 min fixation with ethanol, slides were incubated with anti-EGFR using clone 31G7 (1:50; Life technologies, Zymed) using standard procedures, followed by incubation with the PowerVision Poly-HRP anti-mouse IgG (ImmunoLogic). Sections were counterstained with haematoxylin. RNA isolation, qRT-PCR and RNA sequencing FFPE samples. Method of total RNA isolation from FFPE samples is as described previously 18 . cDNA was obtained by reverse transcription using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, AB) according to the manufacturer's instructions. EGFR expression assay (Hs01076078_m1), SOX10 expression assay (Hs00366918_m1), PDGFRB expression assay (Hs01019589_m1), TGFBR3 expression assay (Hs01114253_m1), TGFBR2 expression assay (Hs00234253_m1), CTGF expression assay (Hs01026927_g1), TAGLN expression assay (Hs01038777_g1), CYR61 expression assay (Hs00998500_g1), JUN expression assay (Hs01103582_s1) and ACTB expression assay (Hs01060665_g1) were used to detect the gene expression on the AB 7500 Fast Real-time PCR system following the manufacturer's instructions. Cell line samples. RNA isolation from cell lines harvested with TRIzol reagent (Invitrogen) according to the manufacturer's instruction. cDNA synthesis was performed with Maxima Universal First Strand cDNA Synthesis Kit (#K1661, Thermo scientific) according to manufacturer's instruction. The primers were used for qRT-PCR are described in Supplementary Table 7 .
For RNA sequencing, the library was prepared using TruSeq RNA sample prep kit according to the manufacturer's protocol (Illumina). RNA sequencing data are available at http://www.ncbi.nlm.nih.gov under accession number GSE50535. LETTER RESEARCH
